DNA repair defects in cancer and therapeutic opportunities
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
DNA repair and DNA damage signaling pathways are critical for the maintenance of genomic stability. Defects of DNA repair and damage signaling contribute to tumorigenesis, but also render cancer cells vulnerable to DNA damage and reliant on remaining repair and signaling activities. Here, we review the major classes of DNA repair and damage signaling defects in cancer, the genomic instability that they give rise to, and therapeutic strategies to exploit the resulting vulnerabilities. Furthermore, we discuss the impacts of DNA repair defects on both targeted therapy and immunotherapy, and highlight emerging principles for targeting DNA repair defects in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 1×
“Human cells rely on a complex network of DNA repair and DNA damage signaling pathways, called the DNA damage response (DDR), to removeDNA lesions and aberrant structures from the genome and maintain genomic stability (Ciccia and Elledge 2010).”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175 · cited 2×
“…AstraZeneca Fong et al. 2009 Rucaparib Clovis Oncology Coleman et al. 2017 Niraparib Tesaro González-Martín et al. 2019 Talazoparib Medivation Litton et al. 2018 Veliparib AbbVie Coleman et al. 2019 AZD5305 AstraZeneca Johannes et al. 2021 ATR Berzosertib (M6620, VX-970) Merck KGaA Yap et…”
BackgroundThe ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Shiloh, Y., & Ziv, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3546 · Cited by 1,649 · cited 1×
“ATM and its downstream kinase CHK2 are important for signaling DSBs (Shiloh and Ziv 2013).”
BackgroundDNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
Self-citationSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Schlacher, K., Wu, H., & Jasin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.015 · Cited by 936 · cited 1×
“2; Schlacher et al. 2011, 2012).”
ATR prohibits replication catastrophe by preventing global exhaustion of RPA
Toledo, L. I., Altmeyer, M., Rask, M.-B., Lukas, C., Larsen, D. H., Povlsen, L. K., Bekker-Jensen, S., Mailand, N., Bartek, J., & Lukas, J. (2013) · Cell · doi:10.1016/j.cell.2013.10.043 · Cited by 911 · cited 1×
“In cancer cells under high replication stress, ATRi induces excessive ssDNA, leading to RPA exhaustion and replication catastrophe (Toledo et al. 2013).”
BackgroundPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666 · cited 1×
“In addition, both ATR and CHK1 are important for HR (Sorensen et al. 2005; Buisson et al. 2017b).”
BackgroundPARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 1×
“In mouse models of BRCA1-deficent ovarian cancer and TNBC, PARPi enhanced the effects of ICIs by eliciting the cGAS–STING pathway (Ding et al. 2018; Pantelidou et al. 2019).”
BackgroundToledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465 · cited 1×
“Cancer cells overexpressing Cyclin E harbor high replication stress and are sensitive to ATRi and CHK1i (Toledo et al. 2011).”
BackgroundWRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458
Adamson, B., Smogorzewska, A., Sigoillot, F. D., King, R. W., & Elledge, S. J. (2012) · Nature Cell Biology · doi:10.1038/ncb2426 · Cited by 433
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382 · cited 1×
“Loss of ARID1A or SMARCA4/BRG1, two components of SWI/SNF chromatin remodeling complexes, alters chromatin compaction, elevates replication stress, and confers ATRi sensitivity (Williamson et al. 2016; Gupta et al. 2020; Kurashima et al. 2020).”
BackgroundSingle-Stranded DNA Orchestrates an ATM-to-ATR Switch at DNA Breaks
Shiotani, B., & Zou, L. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.01.024 · Cited by 353 · cited 1×
“Furthermore, ATMandATR function in concert in DSB signaling (Shiotani and Zou 2009).”
BackgroundSelf-citationBuisson, R., Boisvert, J. L., Benes, C. H., & Zou, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.029 · Cited by 316 · cited 4×
“ATR also alleviates replication stress by promoting dNTP synthesis (Buisson et al. 2015).”
BackgroundInfluentialSelf-citationJohnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291 · cited 1×
“Furthermore, CDK12 inhibition overcomes the PARPi resistance in TNBC by reducing the expression of HR genes (Johnson et al. 2016).”
BackgroundDNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000340 · Cited by 228 · cited 1×
“ATRi also enhances the radiation-induced inflammatory tumor microenvironment (Dillon et al. 2019; Sheng et al. 2020).”
BackgroundVendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198 · cited 1×
“ATRi reduces the expression of PD-L1 in cancer cells, sensitizing them to T-cell-mediated cell killing (Sun et al. 2018; Vendetti et al. 2018).”
BackgroundTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry
Zhao, W., Vaithiyalingam, S., San Filippo, J., Maranon, D. G., Jimenez-Sainz, J., Fontenay, G. V., Kwon, Y., Leung, S. G., Lu, L., Jensen, R. B., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.032 · Cited by 177
Adam, S., Rossi, S. E., Moatti, N., De Marco Zompit, M., Xue, Y., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00266-w · Cited by 121
Chen, J., Harding, S. M., Natesan, R., Tian, L., Benci, J. L., Li, W., Minn, A. J., Asangani, I. A., & Greenberg, R. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108080 · Cited by 111 · cited 2×
“When treated with ATRi, irradiated cancer cells undergo mitosis in the presence of DSBs, increasing micronuclei and activation of the cGAS–STING pathway (Chen et al. 2020).”
Cited by
Extracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
“Abnormal genomic stability can lead to the accumulation of mutations and chromosomal aberrations, which are closely related to cancer, aging and genetic diseases [104].”
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Ning, K., Kuz, C. A., Cheng, F., Feng, Z., Yan, Z., & Qiu, J. (2023) · mBio · doi:10.1128/mbio.03528-22 · Cited by 33
Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
Li, J., Hu, H., He, J., Hu, Y., Liu, M., Cao, B., Chen, D., Ye, X., Zhang, J., Zhang, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101825 · Cited by 4
“A number of studies have reported that combination therapies designed to disrupt HR repair in cancer cells and render vulnerabilities to che-motherapies have shown potent antitumor efficacy [23,24].”
Background
Metadata
- Authors
- Hopkins, J. L., Lan, L., & Zou, L.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2022-03-01
- Volume
- 36
- Issue
- 5-6
- Pages
- 278-293
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4220949372
- Cited by
- 200
- References
- 28
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.